• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2012 Product Image

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2012

  • ID: 2335343
  • November 2012
  • 46 pages
  • Global Markets Direct

Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS). Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Secondary Progressive Multiple Sclerosis (SPMS) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) 7
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics under Development by Companies 9
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics – Products under Development by Companies 13
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Development 15
Opexa Therapeutics, Inc. 15
AB Science 16
Daval International Ltd. 17
Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
natalizumab - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Tcelna - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(R)-Lipoic acid - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
masitinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cyclophosphamide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Aimspro - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Trimesta + Norethindrone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics – Drug Profile Updates 35
Secondary Progressive Multiple Sclerosis (SPMS) – Product Development Milestones 42
Featured News & Press Releases 42
Sep 12, 2012: Opexa Initiates Phase IIb Clinical Trial Of Tcelna In Patients With Secondary Progressive Multiple Sclerosis 42
Aug 23, 2012: Novartis In Partnership With Health Canada To Introduce Revised Product Monograph For Gilenya 43
May 21, 2012: Opexa Announces Tcelna As New Brand Name For MS Therapy 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2012 7
Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Opexa Therapeutics, Inc., H2 2012 15
AB Science, H2 2012 16
Daval International Ltd., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics – Drug Profile Updates 35

List of Figures
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2012 7
Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos